Roivant Sciences Ltd.
ROIV
株式のランク
#980
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company... Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
株価
$33.73
最終同期: 2026-07-31
時価総額
$24.37B
変化（1日）
-2.28%
変化（1年）
88.77%
国
GB
取引 Roivant Sciences Ltd. (ROIV)
カテゴリー
Healthcare
Roivant Sciences Ltd.（ROIV）の収益
Jun 2026 時点の収益 TTM: $7.53M
Roivant Sciences Ltd. の最新の財務報告によると、現在の収益 (TTM) は $7.53M です。2024 年には $32.71M の収益があり、これは 2023 年の $61.28M と比較して 減少 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Roivant Sciences Ltd. の収益履歴（2020 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $7.53M | -74.07% |
| 2025 | $29.05M | -11.19% |
| 2024 | $32.71M | -46.62% |
| 2023 | $61.28M | 10.84% |
| 2022 | $55.29M | 132.34% |
| 2021 | $23.80M | -64.85% |
| 2020 | $67.69M | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| $12.62B | 167,508.87% |
US
|
|
| $2.23B | 29,480.46% |
US
|
|
| $15.74B | 208,932.49% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 79,842.74% |
NL
|
